论文部分内容阅读
目的观察舒利迭对轻中度支气管哮喘Th1/Th2平衡及肺功能的影响。方法选取2011年1月—2013年1月在本院住院的轻、中度支气管哮喘患者116例随机分为试验组(58例)和对照组(58例),试验组采用舒利迭药物治疗,对照组采用沙丁胺醇治疗,观察两组患者治疗前与治疗后1、2个月外周血白细胞介素-4(IL-4)与干扰素-γ(IFN-γ)的水平,及肺功能第1秒用力呼气量(FEV1)和呼气峰流速(PEF)。结果与治疗前比较,两组治疗后1个月及2个月的IL-4明显降低,IFN-γ明显升高,肺功能明显改善,差异均有统计学意义(P<0.05)。与对照组相比,同一时间段试验组的IL-4下降更明显,IFN-γ升高更明显,PEF明显升高,差异均有统计学意义(P<0.05),而FEVl稍为升高,但差异无统计学意义(P>0.05)。结论舒利迭能调节轻中度支气管哮喘患者Th1/Th2平衡,改善肺功能,可有效地治疗轻中度支气管哮喘患者,值得临床推广。
Objective To observe the effects of seretide on Th1 / Th2 balance and lung function in mild to moderate bronchial asthma. Methods One hundred and sixteen patients with mild or moderate bronchial asthma who were hospitalized in our hospital from January 2011 to January 2013 were randomly divided into trial group (58 cases) and control group (58 cases). Patients in trial group were treated with seretide , While the control group was treated with albuterol. The levels of interleukin-4 (IL-4) and interferon-γ (IFN-γ) in the two groups before and after treatment were observed, and lung function 1 second forced expiratory volume (FEV1) and peak expiratory flow (PEF). Results Compared with those before treatment, the levels of IL-4 and IFN-γ in the two groups were significantly decreased at 1 month and 2 months after treatment, and the lung function was significantly improved. The difference was statistically significant (P <0.05). Compared with the control group, the decrease of IL-4 in the experimental group was more obvious at the same time period, the IFN-γlevel was more obvious and PEF was significantly higher (P <0.05), while the FEV1 slightly increased But the difference was not statistically significant (P> 0.05). Conclusion Seretide can regulate Th1 / Th2 balance in patients with mild to moderate bronchial asthma and improve pulmonary function, which can be used to treat patients with mild to moderate bronchial asthma. It is worthy of clinical promotion.